Merck & Co., Inc. (MRK)[Tv]

Key Developments

• FDA Accelerated Approval of KEYTRUDA + Padcev for Neoadjuvant/Adjuvant Muscle-Invasive Bladder Cancer – The FDA’s approval of Merck’s KEYTRUDA in combination with Pfizer’s Padcev marks a transformative milestone as the first and only PD-1 inhibitor/ADC regimen approved for this indication regardless of cisplatin eligibility, unlocking a vast, underserved patient population and reinforcing Merck’s leadership in immuno-oncology.

• $6.7 Billion Acquisition of Terns Pharmaceutical – Merck’s strategic purchase of Terns, a company with advanced oncology assets including TERN-701, significantly strengthens its long-term innovation runway and signals a decisive pivot from Keytruda dependency toward next-generation pipeline development.

• FDA Approval of KEYTRUDA + Trodelvy for First-Line PD-L1-Positive Triple-Negative Breast Cancer – This approval expands Keytruda’s footprint into a high-unmet-need indication, delivering a differentiated, high-value treatment with minimal competition, and positioning Merck to capture substantial market share in a growing oncology segment.

Key Developments

• FDA approves Idvynso, a once-daily two-drug HIV regimen, marking a major milestone in Merck’s strategic pivot into chronic infectious disease management and positioning the company as a leader in next-generation HIV therapy.
• FDA expands approval of CAPVAXIVE to include children and adolescents (2–17) with chronic medical conditions, significantly broadening Merck’s vaccine footprint in high-risk pediatric populations and unlocking substantial new commercial opportunities.
• European Commission approves KEYTRUDA in combination with Padcev for neoadjuvant treatment of muscle-invasive bladder cancer, backed by Phase 3 data showing a 60% improvement in event-free survival and a 50% reduction in death risk—cementing KEYTRUDA’s dominance in immuno-oncology.
• FDA approves KEYTRUDA + Trodelvy combination for first-line treatment of PD-L1-positive triple-negative breast cancer, representing a transformative expansion into a high-unmet-need oncology indication with minimal competition and strong commercial upside.
• U.S. House Select Committee launches formal investigation into Merck’s clinical trial activities in Xinjiang and military-affiliated hospitals, raising severe geopolitical and reputational risks amid growing scrutiny of U.S.-China scientific collaboration.

Key Developments

• European Commission approves KEYTRUDA in combination with Pfizer’s Padcev for neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) – This landmark approval, backed by strong Phase 3 data from KEYNOTE-905, cements Merck’s dominance in immuno-oncology and opens a high-margin, premium-priced revenue stream in a disease area with significant unmet need.

• FDA expands approval of CAPVAXIVE to children and adolescents (2–17) with chronic medical conditions – This regulatory win strengthens Merck’s vaccine franchise and unlocks a high-risk, underserved pediatric market with substantial commercial and public health potential.

• FDA approves Idvynso, a once-daily two-drug HIV regimen, marking a major milestone in Merck’s pivot into chronic infectious disease management – The approval underscores Merck’s growing strength in HIV, complements its pipeline of next-gen regimens, and positions the company as a key player beyond oncology.

Key Developments

• FDA grants Breakthrough Therapy designation to calderasib (MK-1084) in combination with Keytruda for first-line treatment of KRAS G12C-mutated metastatic NSCLC, marking a pivotal validation of Merck’s precision oncology strategy and accelerating development of a high-potential blockbuster therapy with transformative commercial upside.
• FDA approves expanded use of PD-L1 IHC 22C3 pharmDx diagnostic on Dako Omnis platform, strengthening Merck’s integrated diagnostic ecosystem and entrenching its control over KEYTRUDA’s patient selection—creating a self-reinforcing moat that enhances long-term commercial dominance across multiple cancers.
• Positive Phase 3 results in ISLEND-1 and ISLEND-2 trials for once-weekly oral HIV regimen (islatravir/lenacapavir) secured FDA Breakthrough Therapy designation, signaling a potential paradigm shift in HIV management and positioning Merck to challenge Gilead’s leadership in chronic infectious disease.
• FDA approval of Idvynso, a once-daily two-drug HIV regimen, cements Merck’s strategic expansion beyond oncology into high-growth infectious disease markets, demonstrating execution capability and opening a new revenue runway beyond Keytruda.
• EMA’s CHMP issues positive recommendation for Keytruda + Padcev combination in perioperative muscle-invasive bladder cancer (MIBC), representing a potential first-in-class PD-1 inhibitor + ADC combo in the EU, backed by robust Phase III data and signaling a major advance in bladder cancer care.

Key Developments

• EMA issues positive recommendation for KEYTRUDA + Padcev in perioperative treatment of muscle-invasive bladder cancer (MIBC) – Based on the robust Phase III KEYNOTE-905 data, this marks a transformative regulatory validation that could expand KEYTRUDA’s footprint in first-line and earlier-stage oncology, unlocking major revenue potential across EU markets.

• FDA grants Breakthrough Therapy designation to calderasib (MK-1084) + KEYTRUDA for first-line metastatic NSCLC with KRAS G12C mutations – This pivotal advance confirms Merck’s leadership in precision oncology, targeting a historically "undruggable" mutation and positioning a potential blockbuster in one of the largest lung cancer subtypes.

• Positive Phase 3 TroFuse-005 results for sacituzumab tirumotecan (sac-TMT) in advanced endometrial cancer – The first TROP2-directed ADC to show significant survival benefit over chemotherapy in a global Phase III trial, establishing a major therapeutic breakthrough and validating Merck’s TroFuse platform as a sustainable growth engine.

• FDA approves expanded use of PD-L1 IHC 22C3 pharmDx diagnostic on Dako Omnis platform – This deepens Merck’s integration into the KEYTRUDA diagnostic ecosystem, streamlining patient testing and strengthening long-term commercial moat by locking in clinical adoption and market share.